Downregulation of the NK cell activity on xenograft
Downregulation of the NK cell activity on xenograft
批准号:
15390414
负责人:
SHIRAKURA Ryota
金额:
$9.41万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2005
中文摘要
α-E/gHLAE的HLA1结构域完全丧失了细胞表面的表达,而α2结构域的表达与HLAG1一样高。α-3和跨膜结构域的替换没有改变。接下来,我们成功地确定了-147位是人类白细胞抗原-E表达的最关键的点。此外,11或66处的点替换导致了细胞表面表达的增强。然而,双取代(11,147)和三取代(11,66,147)对人NK细胞的抑制作用不如对NK细胞的双重取代(11,147),但对NK细胞的抑制作用不如对人NK细胞的替代147。Delta-SCR2-DAF和Delta-SCR3-DAF不能同时抑制补体介导的和NK介导的PEC裂解。但Delta-SCR4-DAF具有明显的补体调节作用,但对NK细胞无影响。结果表明,DAF通过SCR2-4对NK细胞具有直接的抑制作用。构建了以人类白细胞抗原-G1为跨膜蛋白的FasL基因胞外部分合成的I型膜蛋白。转导FasL-TM的PEC高表达FasL-TM。接下来,作为体外非协调性异种移植的迟发性排斥反应模型,进一步检测了转染物分子对PEC上NK细胞介导的杀伤的改善作用。PIG-α-1,3GT亚克隆了PIG-α-1,3GT基因。并将其导入K562人细胞。随着K562细胞α-Gal表位表达的增加,NK细胞依赖的K562细胞直接裂解作用上调。提示α-Gal表位的NK细胞受体的存在。
英文摘要
HLA-E/GThe substitution of α1 domain of HLA-E completely lost the cell surface expression, however, the α2 domain was expressed very high as same as HLA-G1. The substitution of α3 and transmembrane domain showed no alteration. We next successfully identified position-147 as the most critical point for HLA-E expression. In addition, the point substitution at 11 or 66 led to a enhancement in cell surface expression. However, a dual substitution (11, 147) and a triple substitution (11, 66, 147) are better in expression but not in inhibitory function against human NK cell than the substitution 147.DAF function for NK cellWe report on an investigation of the effect of DAF on NK cell-mediated cytolysis. Delta-SCR2-DAF and delta-SCR3-DAF failed to suppress both complement-mediated and NK-mediated PEC lyses. However, delta-SCR4-DAF showed a clear complement regulatory effect, but had no effect on NK cells. The data suggest DAF has the direct inhibitory function on NK cells via SCR2-4.The Synthesized Type I Membrane Protein of FasLcDNA of the extra cellular portion of the FasL gene with a transmembrane (TM) of HLA-G1 was constructed. The transfectant with FasL-TM was high expressed on PEC.The amelioration of NK cell-mediated lysis by the transfectant molecules on PEC was next tested as an in vitro delayed-type rejection model of a discordant xenograft. The FasL-TM indicated a clear inhibitory effect on NK cell-mediated PEC lysis.pig-α1,3GTThe cDNA of pig-α1,3GT was subcloned. And transfected into K562 human cell. As the K562 transfectants increased the expression of the α-Gal epitope, so the NK cell-dependent direct K562 lysis was up-regulated. The data indicated the existance of the NK cell receptor responsible for the α-Gal epitope.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Cloning the transgenic pigs expressing human decay accelerating factor and N-acetylglucosaminyltransferase III.
克隆表达人类腐烂加速因子和N-乙酰氨基葡萄糖转移酶III的转基因猪。
DOI:
--
发表时间:
2004
期刊:
Cloning and Stem Cells 6
影响因子:
--
作者:
[T Fujimura, S Miyagawa, et al.]
通讯作者:
et al.
Jung-Sik Kim, ----, S.Miyagawa, et al.: "Human cytomegalovirus UL18 Alleviated Human NK mediated Swine Endothelial Cell Lysis"Biochem Biophys Res Commun. (In press). (2004)
Jung-Sik Kim,----,S.Miyakawa,等人:“人类巨细胞病毒 UL18 缓解人类 NK 介导的猪内皮细胞裂解”Biochem Biophys Res Commun。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.1016/j.bbrc.2004.01.027
发表时间:
2004-02-27
期刊:
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
影响因子:
3.1
作者:
[Kim, JS, Choi, SE, Park, CG]
通讯作者:
Park, CG
The feature of decay accelerating factor (DAF:CD55) on natural killer cell-mediated cytotoxicity.
衰变加速因子(DAF:CD55)对自然杀伤细胞介导的细胞毒性的特征。
DOI:
--
发表时间:
2004
期刊:
J.Immunol. 173
影响因子:
--
作者:
[S Miyagawa, et al.]
通讯作者:
et al.
T.Kusama, S.Miyagawa, et al.: "Downregulation of NK cell-mediated swine endothelial cell lysis by (CD55)"Transtrant Proc. 35. 529-530 (2003)
T.Kusama、S.Miyakawa 等人:“(CD55) 下调 NK 细胞介导的猪内皮细胞裂解”Transtrant Proc。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 10 条
The strategy for inhibiting NK cell activity by gene technology
-
批准号:12470273
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$10.3万
-
财政年份:2000
-
负责人:SHIRAKURA Ryota
-
依托单位:
A study of molecular diagnosis and treatment for chronic cardiac allograft rejection.
-
批准号:10557122
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$7.68万
-
财政年份:1998
-
负责人:SHIRAKURA Ryota
-
依托单位:
A study for the in vivo mechanism of transplantation tolerance using GFP transgenic mice
-
批准号:10470274
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.61万
-
财政年份:1998
-
负责人:SHIRAKURA Ryota
-
依托单位:
The study elucidating the molecular mechanisms underlying transplant vasculopathy
-
批准号:08457349
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.99万
-
财政年份:1996
-
负责人:SHIRAKURA Ryota
-
依托单位:
ESTABLISHMENT OF IMMUNOSUPPRRESIVE METHOD FOR CLINICAL XENOTRANSPLANTATION
-
批准号:06454400
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.35万
-
财政年份:1994
-
负责人:SHIRAKURA Ryota
-
依托单位:
The development of xenograft
-
批准号:05557065
-
项目类别:Grant-in-Aid for Developmental Scientific Research (B)
-
资助金额:$12.86万
-
财政年份:1993
-
负责人:SHIRAKURA Ryota
-
依托单位:
The Clonal Analysis of Effector Mechanism in Graft Rejection
-
批准号:01570710
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.28万
-
财政年份:1989
-
负责人:SHIRAKURA Ryota
-
依托单位:
国内基金
海外基金
登录
查看更多内容
LILRB2/HLA-G免疫抑制轴在胶质瘤干细胞免疫逃逸中的作用及其与STAT3信号通路的交互调控机制研究
-
批准号:2026JJ80459
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:王彪
-
依托单位:
HLA-G在胃癌发生发展中的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:章霞
-
依托单位:
PARP抑制剂诱导卵巢癌表达HLA-G介导NK细胞相关免疫逃逸的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
CREPT/p300复合物促进HLA-G乙酰化介导TNBC免疫抑制微环境形成的机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:李维妙
-
依托单位:
rs9378141影响GATA1转录激活HLA-G调节KIR2DL4通路诱导CSU患者肥大细胞脱颗粒机制
-
批准号:82373487
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:肖汀
-
依托单位:
HLA-G在绒毛外滋养细胞特异性表达调控机制的类器官多组学研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:姚元庆
-
依托单位:
预移植过表达HLA-G基因的间充质基质细胞提高心肌内移植的异体心肌细胞存活率的机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:孙思佳
-
依托单位:
肿瘤源性外泌体HLA-G介导TNBC微环境中NK细胞耗竭的作用及机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:郑国旭
-
依托单位:
HLA-G/ILT2调控蜕膜多形核髓系抑制细胞分化促进妊娠维持的机制研究
-
批准号:82101748
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李聪聪
-
依托单位:
肿瘤源性ILT4通过HLA-G/ILT4-STAT5A-PD-L1轴诱导NSCLC相关中性粒细胞促进肿瘤侵袭转移
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:24万元
-
批准年份:2020
-
负责人:王婧男
-
依托单位: